Bivatuzumab

CAS No. 214559-60-1

Bivatuzumab( —— )

Catalog No. M36909 CAS No. 214559-60-1

Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 613 Get Quote
10MG 938 Get Quote
25MG 1454 Get Quote
50MG 1841 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Bivatuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6.
  • Description
    Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells.
  • In Vitro
    Bivatuzumab (10 μg/mL) stains CD44v6 in STS cells.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    214559-60-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167. ?
molnova catalog
related products
  • Hedysarimcoumestan?B

    Hedysarimcoumestan B is a natural product that can be isolated from the roots of Hedysarum multijugum.

  • Morusinol

    Morusinol is a flavonoid extracted from the root bark of Morus alba.

  • ML-180

    ML-180 is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist (IC50 of 3.7 μM) .ML-180 (0.5-5 μM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells[2]. ML-180 (5 μM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling.